Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-08 23:06 | 2025-09-04 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Officer | SELL | $13.29 | 1,038 | $13,794 | 94,873 |
| 2025-09-08 23:03 | 2025-09-04 | DYN | Dyne Therapeutics, Inc. | Kerr Douglas | Officer | SELL | $13.30 | 4,425 | $58,842 | 88,390 |
| 2025-09-09 03:32 | 2025-09-04 | NKTR | NEKTAR THERAPEUTICS | Zalevsky Jonathan | Officer | SELL | $33.52 | 1,721 | $57,693 | 17,462 |
| 2025-09-09 00:14 | 2025-09-04 | ARQT | Arcutis Biotherapeutics Inc. | Matsuda Masaru | Officer | SELL | $16.16 | 36,130 | $583,716 | 161,234 |
| 2025-09-09 01:05 | 2025-09-04 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $52.20 | 80,000 | $4,175,832 | 875,686 |
| 2025-09-08 23:38 | 2025-09-04 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $35.54 | 98,660 | $3,506,278 | 44,452 |
| 2025-09-08 23:37 | 2025-09-04 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Officer | SELL | $35.31 | 3,523 | $124,397 | 9,415 |
| 2025-09-08 21:01 | 2025-09-05 | RARE | Ultragenyx Pharmaceutical Inc. | Huizenga Theodore Alan | Officer | SELL | $31.39 | 84 | $2,637 | 50,306 |
| 2025-09-09 01:55 | 2025-09-04 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.91 | 8,999 | $17,202 | 1,895,756 |
| 2025-09-09 02:06 | 2025-09-04 | AQST | Aquestive Therapeutics Inc. | Jung Cassie | Officer | OPT+S | $5.00 | 62,180 | $310,900 | 283,346 |
| 2025-09-09 00:13 | 2025-09-05 | AQST | Aquestive Therapeutics Inc. | Boyd Peter E. | Officer | SELL | $5.30 | 15,000 | $79,500 | 288,323 |
| 2025-09-09 00:37 | 2025-09-04 | PCRX | Pacira BioSciences, Inc. | Ceesay Abraham | Director | SELL | $27.19 | 2,354 | $64,005 | 9,039 |
| 2025-09-09 01:45 | 2025-09-08 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | Director, Officer | OPT+S | $16.41 | 157,307 | $2,582,021 | 298,661 |
| 2025-09-08 23:31 | 2025-09-05 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Khattar Jack A. | Director, Officer | OPT+S | $46.01 | 55,578 | $2,557,144 | 1,110,231 |
| 2025-09-09 00:59 | 2025-09-04 | MLYS | Mineralys Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | $25.50 | 1,176,470 | $29,999,985 | 5,456,521 |
| 2025-09-09 01:06 | 2025-09-05 | BBIO | BridgeBio Pharma, Inc. | MCCORMICK FRANK | Director | OPT+S | $53.16 | 74,000 | $3,933,544 | 83,275 |
| 2025-09-09 03:07 | 2025-09-04 | MLYS | Mineralys Therapeutics, Inc. | AKKARAJU SRINIVAS | Director | BUY | $25.50 | 588,235 | $14,999,993 | 588,235 |
| 2025-09-09 03:31 | 2025-09-04 | NKTR | NEKTAR THERAPEUTICS | ROBIN HOWARD W | Director, Officer | SELL | $36.42 | 11,832 | $430,958 | 56,008 |
| 2025-09-09 02:53 | 2025-09-08 | BSPK | Bespoke Extracts, Inc. | FEINSOD MICHAEL | Director, Officer, 10% owner | BUY | $0.19 | 2,500 | $475 | 2,508,612 |
| 2025-09-05 23:03 | 2025-09-04 | SION | Sionna Therapeutics, Inc. | Fitzpatrick Jennifer | Officer | OPT+S | $23.12 | 10,250 | $236,980 | 0 |
| 2025-09-06 00:06 | 2025-09-03 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | Officer | SELL | $25.09 | 18,073 | $453,452 | 15,000 |
| 2025-09-05 23:30 | 2025-09-03 | LQDA | Liquidia Corp | SINGH RAMAN | Director | SELL | $29.42 | 7,500 | $220,650 | 31,255 |
| 2025-09-06 01:00 | 2025-09-04 | JNJ | JOHNSON & JOHNSON | Taubert Jennifer L | Officer | OPT+S | $177.81 | 56,471 | $10,040,883 | 178,013 |
| 2025-09-06 02:48 | 2025-09-05 | RCUS | Arcus Biosciences, Inc. | Azoy Alexander | Officer | SELL | $11.88 | 1,579 | $18,758 | 30,194 |
| 2025-09-06 00:01 | 2025-09-03 | ROIV | Roivant Sciences Ltd. | Ramaswamy Vivek | 10% owner | SELL | $12.65 | 1,775,749 | $22,456,122 | 35,508,359 |
| 2025-09-06 01:56 | 2025-09-05 | RNA | Avidity Biosciences, Inc. | Boyce Sarah | Director, Officer | OPT+S | $49.95 | 50,000 | $2,497,435 | 305,871 |
| 2025-09-06 01:32 | 2025-09-03 | RNA | Avidity Biosciences, Inc. | Mosbrooker Eric | Officer | OPT+S | $47.07 | 6,563 | $308,936 | 55,000 |
| 2025-09-05 23:05 | 2025-09-03 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | Officer | SELL | $18.51 | 573 | $10,608 | 92,083 |
| 2025-09-06 00:00 | 2025-09-03 | CPRX | CATALYST PHARMACEUTICALS, INC. | Elsbernd Brian | Officer | OPT+S | $19.74 | 50,000 | $987,200 | 188,564 |
| 2025-09-06 00:46 | 2025-09-04 | PGEN | PRECIGEN, INC. | AGEE NANCY H | Director | BUY | $4.60 | 15,000 | $69,000 | 217,841 |
| 2025-09-06 02:43 | 2025-09-05 | AXSM | Axsome Therapeutics, Inc. | Saad Mark E | Director | OPT+S | $125.07 | 9,127 | $1,141,514 | 10,002 |
| 2025-09-06 02:14 | 2025-09-05 | BSPK | Bespoke Extracts, Inc. | FEINSOD MICHAEL | Director, Officer, 10% owner | BUY | $0.20 | 2,500 | $500 | 2,506,112 |
| 2025-09-05 23:30 | 2025-09-04 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $385.21 | 11,000 | $4,237,281 | 36,781 |
| 2025-09-05 03:36 | 2025-09-03 | IONS | IONIS PHARMACEUTICALS INC | Devers Shannon L. | Officer | OPT+S | $61.02 | 3,162 | $192,943 | 15,009 |
| 2025-09-05 03:28 | 2025-09-03 | IONS | IONIS PHARMACEUTICALS INC | Schneider Eugene | Officer | OPT+S | $60.81 | 19,658 | $1,195,421 | 51,507 |
| 2025-09-05 00:37 | 2025-09-02 | ARWR | Arrowhead Pharmaceuticals Inc. | Hamilton James C | Officer | SELL | $25.00 | 15,000 | $375,000 | 247,122 |
| 2025-09-05 03:34 | 2025-09-03 | IONS | IONIS PHARMACEUTICALS INC | Baroldi Joseph | Officer | OPT+S | $59.34 | 32,800 | $1,946,221 | 16,926 |
| 2025-09-05 03:41 | 2025-09-02 | IONS | IONIS PHARMACEUTICALS INC | Swayze Eric | Officer | SELL | $49.67 | 11,130 | $552,862 | 37,302 |
| 2025-09-05 04:02 | 2025-09-02 | NKTR | NEKTAR THERAPEUTICS | Zalevsky Jonathan | Officer | SELL | $30.10 | 485 | $14,599 | 19,183 |
| 2025-09-05 01:41 | 2025-09-02 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | OPT+S | $15.64 | 10,000 | $156,383 | 100,206 |
| 2025-09-05 02:47 | 2025-09-02 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | Officer | OPT+S | $46.08 | 12,500 | $576,035 | 197,484 |
| 2025-09-04 23:30 | 2025-09-02 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Officer | OPT+S | $32.10 | 5,000 | $160,500 | 96,270 |
| 2025-09-05 00:29 | 2025-09-02 | ONC | BeOne Medicines Ltd. | Ball Titus B. | Officer | SELL | $326.76 | 122 | $39,865 | 0 |
| 2025-09-04 23:30 | 2025-09-02 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Shulman Joseph | Officer | OPT+S | $105.30 | 16,781 | $1,767,006 | 8,509 |
| 2025-09-05 03:29 | 2025-09-02 | IONS | IONIS PHARMACEUTICALS INC | O'NEIL PATRICK R. | Officer | OPT+S | $60.03 | 89,900 | $5,396,841 | 7,330 |
| 2025-09-05 03:38 | 2025-09-03 | IONS | IONIS PHARMACEUTICALS INC | Monia Brett P | Director, Officer | OPT+S | $60.32 | 203,814 | $12,294,713 | 180,009 |
| 2025-09-04 23:30 | 2025-09-02 | ANNX | Annexon, Inc. | Carson William H. | Director | BUY | $2.09 | 4,115 | $8,600 | 37,945 |
| 2025-09-04 23:53 | 2025-09-03 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Officer | SELL | $6.78 | 12 | $81 | 9,463 |
| 2025-09-05 03:37 | 2025-09-02 | IONS | IONIS PHARMACEUTICALS INC | Geary Richard S | Officer | SELL | $50.37 | 10,000 | $503,671 | 79,657 |
| 2025-09-04 21:29 | 2025-08-13 | DMAC | DiaMedica Therapeutics Inc. | STAHLBERG JAN | 10% owner | BUY | $5.96 | 1,000,000 | $5,958,100 | 7,764,465 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.